Overactive Bladder Treatment (OAB) Market

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 21)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 26)
    2.1 RESEARCH APPROACH
           2.1.1 PRIMARY RESEARCH
           2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES
    2.2 DATA TRIANGULATION APPROACH
           2.2.1 SECONDARY RESEARCH
           2.2.2 COVID-19-SPECIFIC ASSUMPTIONS
    2.3 RESEARCH LIMITATIONS
    2.4 RISK ASSESSMENT
    2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
           2.5.1 SUPPLY SIDE
           2.5.2 DEMAND SIDE
                    2.5.2.1 Insights from primary experts

3 EXECUTIVE SUMMARY (Page No. - 34)

4 PREMIUM INSIGHTS (Page No. - 37)
    4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
    4.2 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021)
    4.3 OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027
    4.4 OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW (Page No. - 41)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Rising prevalence of overactive bladder syndrome
                    5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB
                    5.2.1.3 Development and use of innovative intravesical therapies
                    5.2.1.4 Growing R&D investments and the launch of novel therapies in the coming years
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 Frequent product recalls
                    5.2.2.2 Increased side-effects of anticholinergic drugs
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Social stigma and lack of awareness about OAB
    5.3 IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET
    5.4 IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    5.6 VALUE CHAIN ANALYSIS
    5.7 SUPPLY CHAIN ANALYSIS
    5.8 ECOSYSTEM ANALYSIS
    5.9 REGULATORY SCENARIO
           5.9.1 PHARMACEUTICAL INDUSTRY
                    5.9.1.1 Regulatory requirements
                               5.9.1.1.1 EU regulations
                               5.9.1.1.2 US regulations
           5.9.2 MEDICAL DEVICE INDUSTRY
                    5.9.2.1 Regulatory requirements
                               5.9.2.1.1 EU regulations
                               5.9.2.1.2 US regulations
    5.10 TECHNOLOGY ANALYSIS
    5.11 KEY CONFERENCES AND EVENTS IN 2022–2023
    5.12 PATENT ANALYSIS
    5.13 PORTER’S FIVE FORCES ANALYSIS
           5.13.1 THREAT FROM NEW ENTRANTS
           5.13.2 THREAT FROM SUBSTITUTES
           5.13.3 BARGAINING POWER OF BUYERS
           5.13.4 BARGAINING POWER OF SUPPLIERS
           5.13.5 DEGREE OF COMPETITION
    5.14 PRICING ANALYSIS
    5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    5.16 PIPELINE ANALYSIS

6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE (Page No. - 64)
    6.1 INTRODUCTION
    6.2 MIRABEGRON
           6.2.1 FEWER SIDE-EFFECTS COMPARED TO ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT
    6.3 ANTICHOLINERGICS
           6.3.1 SOLIFENACIN
                    6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence—a key factor driving market growth
           6.3.2 OXYBUTYNIN
                    6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market
           6.3.3 FESOTERODINE
                    6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions
           6.3.4 DARIFENACIN
                    6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent
           6.3.5 TOLTERODINE
                    6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side-effects and offers long-term clinical efficacy
           6.3.6 TROSPIUM
                    6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low
           6.3.7 OTHER ANTICHOLINERGICS
    6.4 BOTOX
           6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE
    6.5 NEUROMODULATION
           6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT
    6.6 OTHER TREATMENTS

7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE (Page No. - 77)
    7.1 INTRODUCTION
    7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME
           7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET
    7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME
           7.3.1 PARKINSON'S DISEASE
                    7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson’s disease to drive market growth
           7.3.2 STROKES
                    7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment
           7.3.3 MULTIPLE SCLEROSIS
                    7.3.3.1 Favorable reimbursement policies to support the growth of the OAB treatment market for MS
           7.3.4 SPINAL CORD INJURIES
                    7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market
           7.3.5 OTHER DISORDERS

8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION (Page No. - 87)
    8.1 INTRODUCTION
    8.2 NORTH AMERICA
           8.2.1 US
                    8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment
           8.2.2 CANADA
                    8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder will drive market growth in Canada
    8.3 EUROPE
           8.3.1 GERMANY
                    8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany
           8.3.2 UK
                    8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth in the OAB market
           8.3.3 FRANCE
                    8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent
           8.3.4 ITALY
                    8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers
           8.3.5 SPAIN
                    8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market
           8.3.6 REST OF EUROPE
    8.4 ASIA PACIFIC
           8.4.1 JAPAN
                    8.4.1.1 Advancements in treatment options to fuel growth in the market in Japan
           8.4.2 CHINA
                    8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market
           8.4.3 INDIA
                    8.4.3.1 India is the world’s largest producer of generic drugs—a key factor driving market growth
           8.4.4 AUSTRALIA
                    8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia—a major factor supporting the growth of this market
           8.4.5 REST OF ASIA PACIFIC
    8.5 LATIN AMERICA
           8.5.1 BRAZIL
                    8.5.1.1 Increased use of overactive bladder drugs in the country to drive growth in the market
           8.5.2 MEXICO
                    8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico
           8.5.3 REST OF LATIN AMERICA
    8.6 MIDDLE EAST & AFRICA
           8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA

9 COMPETITIVE LANDSCAPE (Page No. - 138)
    9.1 INTRODUCTION
    9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    9.3 MARKET SHARE ANALYSIS
    9.4 REVENUE ANALYSIS
    9.5 COMPANY EVALUATION QUADRANT
           9.5.1 STARS
           9.5.2 EMERGING LEADERS
           9.5.3 PERVASIVE PLAYERS
           9.5.4 PARTICIPANTS
    9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS
           9.6.1 COMPANY FOOTPRINT (20 COMPANIES)
           9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES)
           9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
    9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
           9.7.1 PROGRESSIVE COMPANIES
           9.7.2 STARTING BLOCKS
           9.7.3 RESPONSIVE COMPANIES
           9.7.4 DYNAMIC COMPANIES
           9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    9.8 COMPETITIVE SCENARIO AND TRENDS
           9.8.1 PRODUCT LAUNCHES & APPROVALS
           9.8.2 DEALS

10 COMPANY PROFILES (Page No. - 152)
     10.1 KEY PLAYERS
             10.1.1 ASTELLAS PHARMA INC.
                        10.1.1.1 Business overview
                        10.1.1.2 Products offered
                        10.1.1.3 MnM view
                                     10.1.1.3.1 Key strengths
                                     10.1.1.3.2 Strategic choices made
                                     10.1.1.3.3 Weaknesses and competitive threats
             10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
                        10.1.2.1 Business overview
                        10.1.2.2 Products offered
                        10.1.2.3 Recent developments
                        10.1.2.4 MnM view
                                     10.1.2.4.1 Key strengths
                                     10.1.2.4.2 Strategic choices made
                                     10.1.2.4.3 Weaknesses and competitive threats
             10.1.3 PFIZER INC.
                        10.1.3.1 Business overview
                        10.1.3.2 Products offered
                        10.1.3.3 MnM view
                                     10.1.3.3.1 Key strengths
                                     10.1.3.3.2 Strategic choices made
                                     10.1.3.3.3 Weaknesses and competitive threats
             10.1.4 ABBVIE INC.
                        10.1.4.1 Business overview
                        10.1.4.2 Products offered
                        10.1.4.3 Recent developments
             10.1.5 VIATRIS INC.
                        10.1.5.1 Business overview
                        10.1.5.2 Products offered
             10.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
                        10.1.6.1 Business overview
                        10.1.6.2 Products offered
             10.1.7 JOHNSON & JOHNSON SERVICES, INC.
                        10.1.7.1 Business overview
                        10.1.7.2 Products offered
             10.1.8 ENDO PHARMACEUTICALS INC.
                        10.1.8.1 Business overview
                        10.1.8.2 Products offered
             10.1.9 LUPIN
                        10.1.9.1 Business overview
                        10.1.9.2 Products offered
             10.1.10 AMNEAL PHARMACEUTICALS LLC
                        10.1.10.1 Business overview
                        10.1.10.2 Products offered
             10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
                        10.1.11.1 Business overview
                        10.1.11.2 Products offered
             10.1.12 GLENMARK
                        10.1.12.1 Business overview
                        10.1.12.2 Products offered
             10.1.13 MACLEODS PHARMACEUTICALS LTD.
                        10.1.13.1 Business overview
                        10.1.13.2 Products offered
             10.1.14 MEDTRONIC
                        10.1.14.1 Business overview
                        10.1.14.2 Products offered
                        10.1.14.3 Recent developments
             10.1.15 AJANTA PHARMA
                        10.1.15.1 Business overview
                        10.1.15.2 Products offered
             10.1.16 GRANULES INDIA LIMITED
                        10.1.16.1 Business overview
                        10.1.16.2 Products offered
     10.2 OTHER PLAYERS
             10.2.1 UROVANT SCIENCES
                        10.2.1.1 Business overview
                        10.2.1.2 Products offered
                        10.2.1.3 Recent developments
             10.2.2 APOTEX INC.
                        10.2.2.1 Business overview
                        10.2.2.2 Products offered
             10.2.3 LABORIE
                        10.2.3.1 Business overview
                        10.2.3.2 Products offered
             10.2.4 INTAS PHARMACEUTICALS LTD.
                        10.2.4.1 Business overview
                        10.2.4.2 Products offered
             10.2.5 BAYER AG
                        10.2.5.1 Business overview
                        10.2.5.2 Pipeline products
             10.2.6 MEDYTOX
                        10.2.6.1 Business overview
                        10.2.6.2 Pipeline products
             10.2.7 ALTHERX PHARMACEUTICALS
                        10.2.7.1 Business overview
                        10.2.7.2 Pipeline products
             10.2.8 TAIHO PHARMACEUTICAL CO., LTD.
                        10.2.8.1 Business overview
                        10.2.8.2 Pipeline products
             10.2.9 HUGEL, INC.
                        10.2.9.1 Business overview
                        10.2.9.2 Pipeline products

11 APPENDIX (Page No. - 192)
     11.1 DISCUSSION GUIDE
     11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     11.3 AVAILABLE CUSTOMIZATIONS
     11.4 RELATED REPORTS
     11.5 AUTHOR DETAILS

LIST OF TABLES (156 Tables)

TABLE 1 OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS
TABLE 2 LIST OF REGULATORY AUTHORITIES
TABLE 3 OVERACTIVE BLADDER TREATMENT MARKET: LIST OF CONFERENCES AND EVENTS
TABLE 4 OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
TABLE 5 OVERACTIVE BLADDER TREATMENT MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS (GENERICS)
TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
TABLE 9 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 10 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 11 OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020–2027 (USD MILLION)
TABLE 12 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 14 OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN, BY REGION, 2020–2027 (USD MILLION)
TABLE 15 OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 21 OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION, BY REGION, 2020–2027 (USD MILLION)
TABLE 23 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 25 IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 26 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 28 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION)
TABLE 29 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES, BY REGION, 2020–2027 (USD MILLION)
TABLE 30 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 32 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020–2027 (USD MILLION)
TABLE 33 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 34 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 36 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 39 US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 42 US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 45 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 46 CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 51 EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 55 GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK
TABLE 57 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 59 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 60 UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE
TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 65 FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 69 ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 72 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 73 SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 74 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 77 REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 78 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 83 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 86 JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 90 CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 91 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 92 INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 93 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 94 INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 99 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 104 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 115 MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 124 OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION
TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
TABLE 128 OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 129 OVERACTIVE BLADDER TREATMENT MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [START-UPS/SMES]
TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2022
TABLE 131 DEALS, JANUARY 2019–MAY 2022
TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
TABLE 134 PFIZER INC.: BUSINESS OVERVIEW
TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW
TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW
TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW
TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW
TABLE 140 LUPIN: BUSINESS OVERVIEW
TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW
TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
TABLE 143 GLENMARK: BUSINESS OVERVIEW
TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
TABLE 145 MEDTRONIC: BUSINESS OVERVIEW
TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW
TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW
TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW
TABLE 149 APOTEX INC.: BUSINESS OVERVIEW
TABLE 150 LABORIE: BUSINESS OVERVIEW
TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
TABLE 152 BAYER AG: BUSINESS OVERVIEW
TABLE 153 MEDYTOX: BUSINESS OVERVIEW
TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW
TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW

LIST OF FIGURES (48 Figures)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE 2022 VS. 2027 (USD MILLION)
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH
FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021
FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2027
FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 13 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60, 2015 VS. 2030 VS. 2050
FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
FIGURE 18 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF PROMINENT COMPANIES
FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY
FIGURE 21 LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE IN THE BUYING PROCESS
FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS
FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS
FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP), 2004–2050
FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 29 OVERACTIVE BLADDER TREATMENT MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
FIGURE 31 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2021
FIGURE 32 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)
FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021)
FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021)
FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021)
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)
FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)
FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021)
FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)
FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021)
FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021)
FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021)
FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)